P098 Therapeutic potential of IFN inducer in multiple sclerosis

Abstract

Introduction Multiple sclerosis (MS) is the socio-significant disease, which leads to disability of patients. Known, that in MS etiopatogenesis are involved the viruses, functional capacity disorders of cells the innate and adaptive immunity. The IFN inducer drugs, in particular, cycloferon,have anti-inflammatory, antiviral and immunomodulatory properties, which could have beneficial effects in immune mediated neurological disorders. Methods We report the results observed on 22 patients with the relapsing-remitting MS (in stages of remission 17 patients and an exacerbation 5 patients) after 1 months of therapy with cycloferon. All the subjects were recruited and treated at the neurological department of MRSRCI. Our patients consisted basically in women with a mean disease duration of 3.35 ± 2.85 years, with mild to moderate severity (EDSS average power at remission was 4 points, in aggravation- 9.2 points). The cycloferon scheme in MS: 1 injection (0.25 g) every other day for a month, on a course of injections15 +vascular therapy. The control group was represented by 17 patients with MS cerebrospinal shape received only the vascular therapy. Results All MS patients IFN-producing capacity by peripheral blood leukocytes (PBL) compared with healthy subjects was significantly reduced: a-IFN/g-IFN in the 5.49/3.1 times in the acute stage and 3.24/2.4 times in remission remitting form of the disease. It should be noted that the most significant decrease in a- and g-IFN-producing ability of PBL was determined in the acute stage relapsing-remitting forms of MS, which correlated with the clinical manifestations of disease. The content of IgG-antibodies to MBP in MS patients with any form of the disease was significantly increased. As a result of treatment clinical improvement was noted with the positive dynamics of neurologic status in cycloferon treated patients. Our results show a EDSS decrease in 7 (32%) patients, EDSS increase in 2 (9%) patients, with the remaining 13 (59%) patients had EDSS did not change. It may be noted that the deficit was initially detectable product a-IFN blood leukocytes of MS patients during treatment to correct the increase of production capacity for a-IFN, reduction of IgG-antibodies to MBP. 15 patients in remission were followed up after treatment with cycloferon 2 times a week for 1.3 years. All patients had pre- treatment exacerbation of the disease in 4, 6, 8 or 12 months. After treatment of 6 patients who had exacerbation in six months, in 4 (66.7%) -long-term remission during the observation period. Among the 9 patients who had exacerbation of disease during the period from 6 to 12 months in 7 patients (77.8%) on cycloferon had stable neurological condition for 15 months. Special attention should be reducing the frequency of exacerbations and longer duration of remission in patients in cycloferon therapy. Long-term observation period of 4 years had 3 patient, 12 years have 1 patient who received cycloferon constantly 2 times a week showed the stability of neurological status. Conclusion Stabilization of clinical current MS, improvement of the IFN-status parameters, decrease in a level of antibodies to myelin basic protein are achieved, that is the basis to consider application low-molecular IFN inducer cycloferon as the alternative approach in MS.